Oxytocin, also known as the “love hormone,” is a female reproductive hormone that is created in the hypothalamus and released into the circulation during childbirth. In a nursing mother, this hormone stimulates labor and milk production. Oxytocic medications can be used as a uterotonic to help induce labor and prevent hemorrhage after a C-section. Aside from that, oxytocic medications are used to treat post-mature birth, uterine atony, pre-eclampsia (high blood pressure during pregnancy), stillbirth, postpartum hemorrhage, and as adjuvant therapy for autism treatment and incomplete abortion.
Every year, more than 15 million babies are delivered prematurely, according to the World Health Organization, and this figure is anticipated to rise in the future years. According to the National Center for Health Statistics, the United States alone had a labor induction rate of 20.9 % in 2012. Based on these figures, the demand for oxytocic medications is likely to skyrocket shortly.
In 2020, for example, Iconovo announced a new development cooperation with Monash University for inhaled oxytocin ICOone manufacturing. The deal stretches Monash the exclusive global right to use ICOone in combination with oxytocin to prevent postpartum hemorrhage in new mothers, this factor boosted the growth of the market. This development contributes to Iconovo’s industrial experience and allows the company to harness its breathing expertise in future initiatives.
Europe is expected to emerge as the second-largest market for oxytocic due to the upsurge in oxytocin administration in response to the increasing number of appointed caesareans procedures. Further, innovations by the top market players such as GlaxoSmithKline Plc and Novartis AG are likely to boost the growth of the market in the forecast period. Moreover, Due to an increase in the prevalence of delivering children at home, which reduces the execution of injections immediately after delivery, as well as a lack of oxytocic drugs and healthcare infrastructure facilities, developing countries in the Asia Pacific, the MEA have a gigantic potential for development in the oxytocic pharmaceuticals market.
Despite a huge decline in the sales of Treatment Types during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 4.3%, during the tenure of 2021 – 2027.
The report published by Maximize encompasses the market dynamics, which could affect the market growth of Oxytocic Pharmaceuticals in the region, the Value – Chain Analysis, and the PORTER’s analysis for the Oxytocic Pharmaceuticals market at a global level. The study is associated based on major segments and further into sub-segments, by Treatment Type (Pre-eclampsia/Eclampsia, Postpartum Hemorrhage, Others) and End-User (Hospitals, Maternity Centre, Clinics) to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2020, considering 2020 as the base year.
Lastly, the market research report provides a regional comparison and a complete country-level analysis for the latest trends, along with the major key players- App Pharmaceuticals LLC, Teva Parenteral Medicines Inc., Abbott laboratories, JHP Pharmaceuticals LLC, Novartis Pharmaceuticals Corporation, LBS Labs, Baxter Healthcare Corporation, Pfizer Inc, Fresenius Kaci, Biofutura, Ferring, Biofutura SpA, Dr. Reddy’s Laboratories, Granules Pharmaceuticals, Inc.,
You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Global Oxytocic Pharmaceuticals Market.”
https://www.maximizemarketresearch.com/market-report/global-oxytocic-pharmaceuticals-market/121354/
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
3rd Floor, Office no. 4,
Navale IT Zone Phase-2,
Mumbai -Bangalore bypass highway,
Pune- 411041
Maharashtra, India
+91 9607195908